| # | Company | Location | Employees | Total Funding | Last Round | Last Funded |
|---|---|---|---|---|---|---|
| 1 |
Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer a…
|
Cambridge | 101 - 250 | $624.3M | Series E | 2025-03-13 |
| 2 |
Alvotech
Alvotech is a biotechnology company that specializes in making biosimilars to cr…
|
Reykjav├¡k | — | $2.0B | Post Ipo Debt | 2025-12-31 |
| 3 |
Nuclera
Nuclera offers a protein prototyping system to accelerate drug discovery by maki…
|
Cambridge | — | $157.8M | Series C | 2026-01-13 |
| 4 |
Orca Bio
Orca Bio is a clinical-stage cell therapy company dedicated to delivering curati…
|
Menlo Park | 251 - 500 | $542.0M | Series F | 2026-01-09 |
| 5 |
Apprentice.io
The industry's first agentic AI manufacturing platform built for a world beyond …
|
Jersey City | 101 - 250 | $207.0M | Series C | 2023-03-20 |
| 6 |
Parabilis Medicines
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specialize…
|
Cambridge | 101 - 250 | $835.3M | Series F | 2026-01-08 |
| 7 |
Ventyx Biosciences
Ventyx is a biopharmaceutical company focused on advancing oral therapies for pa…
|
San Diego | 101 - 250 | $468.6M | Post Ipo Equity | 2024-09-23 |
| 8 |
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, an…
|
Paris | c 10001 max | $7.0B | Post Ipo Debt | 2025-10-28 |
| 9 |
Exciva
Exciva develops clinical-stage biopharmaceutical therapies focused on addressing…
|
Heidelberg | 1 - 10 | $69.8M | Series B | 2026-01-20 |
| 10 |
Metsera
Metsera is a clinical-stage biotech firm developing oral & injectable hormone th…
|
New York | 51 - 100 | $505.0M | Series B | 2024-11-13 |
| 11 |
Invivyd
Invivyd develops antibodies to transcend the limitations of the human immune sys…
|
Waltham | 101 - 250 | $678.5M | Post Ipo Equity | 2025-11-17 |
| 12 |
b.well Connected Health
B.well Connected Health is a digital health platform that provides individuals w…
|
Baltimore | 101 - 250 | $118.8M | Debt Financing | 2025-07-30 |
| 13 |
FibroBiologics
FibroBiologics is a regenerative medicine company developing an innovative solut…
|
Houston | 11 - 50 | $145.2M | Post Ipo Equity | 2026-03-31 |
| 14 |
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutic…
|
San Francisco | 1 - 10 | $142.0M | Series B | 2025-12-16 |
| 15 |
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology o…
|
San Diego | 101 - 250 | $854.0M | Post Ipo Equity | 2026-01-21 |
| 16 |
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery,…
|
Cambridge | 1K - 5K | $4.5B | Post Ipo Debt | 2025-09-09 |
| 17 |
Medable
Medable is transforming clinical research and predictive medicine by creating a …
|
Palo Alto | 501 - 1K | $506.6M | Series D | 2021-10-26 |
| 18 |
Lisata Therapeutics
Lisata Therapeutics is a clinical-stage biopharmaceutical company.
|
Basking Ridge | 11 - 50 | $165.6M | Grant | 2021-05-12 |
| 19 |
Pfizer
Pfizer is a biopharmaceutical company that discovers, develops, and delivers med…
|
New York | c 10001 max | $38.0B | Post Ipo Debt | 2025-11-21 |
| 20 |
Cytotheryx
Cytotheryx is a preclinical cell therapy company focused on the development of a…
|
Rochester | 11 - 50 | $60.0M | Debt Financing | 2026-01-12 |
| 21 |
BlossomHill Therapeutics
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and…
|
San Diego | 11 - 50 | $257.0M | Series B | 2025-12-10 |
| 22 |
Corona Remedies
Corona Remedies is a pharmaceutical company manufacturing tablet, capsules, syru…
|
Ahmedabad | 1K - 5K | $109.0M | Secondary Market | 2021-04-05 |
| 23 |
Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development of me…
|
New York | 501 - 1K | $2.5B | Post Ipo Equity | 2023-02-02 |
| 24 |
Addition Therapeutics
Addition Therapeutics develops RNA-only therapeutics using PRINT technology for …
|
South San Francisco | 11 - 50 | $100.0M | Series A | 2025-12-17 |
| 25 |
Insitro
Insitro is a drug discovery and development startup that utilizes machine learni…
|
South San Francisco | 251 - 500 | $643.0M | Series C | 2021-03-15 |
| 26 |
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseas…
|
Cambridge | 11 - 50 | $199.0M | Series B | 2023-09-12 |
| 27 |
Judi Health
Judi Health is a healthtech platform that provides pharmacy benefit management s…
|
New York | 501 - 1K | $736.0M | Series F | 2025-09-23 |
| 28 |
Novartis
Novartis is a pharmaceutical company that researches and develops medicines for …
|
Basel | c 10001 max | $2.5B | Post Ipo Debt | 2024-06-19 |
| 29 |
Day One Biopharmaceuticals
Day One Biopharmaceuticals develops targeted therapies to treat people with life…
|
South San Francisco | 101 - 250 | $687.5M | Post Ipo Equity | 2024-07-30 |
| 30 |
NRG Therapeutics
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches …
|
Cambridge | 11 - 50 | $97.3M | Series B | 2025-09-08 |
| 31 |
reprai
SaaS, B2B, Entreprise, Marketing and Sales, Pharma
|
Wilmington | 1 - 10 | $1.0M | Pre Seed | 2025-09-01 |
| 32 |
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating…
|
Cambridge | 101 - 250 | $823.4M | Post Ipo Equity | 2026-03-27 |
| 33 |
Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the devel…
|
San Mateo | 11 - 50 | $242.2M | Series C | 2024-05-09 |
| 34 |
DISCO Pharmaceuticals
DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unloc…
|
Cologne | 11 - 50 | $64.0M | Seed | 2025-12-11 |
| 35 |
Zenas BioPharma
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune…
|
Waltham | 101 - 250 | $713.0M | Post Ipo Debt | 2026-03-26 |
| 36 |
Massive Bio
Massive Bio is an AI powered oncology platform that connects patients to clinica…
|
New York | 101 - 250 | $23.8M | Series B | 2022-06-02 |
| 37 |
OS Therapies
OS Therapies is a therapeutics company focused on the identification, developmen…
|
Rockville | 1 - 10 | $37.1M | Post Ipo Equity | 2026-04-02 |
| 38 |
Tubulis
Tubulis generates antibody-drug conjugates with unique properties for solid tumo…
|
Munich | 51 - 100 | $616.9M | Series C | 2025-10-15 |
| 39 |
Amgen
Amgen is a biotechnology company that develops and manufactures human therapeuti…
|
Thousand Oaks | c 10001 max | $28.5B | Post Ipo Debt | 2022-12-12 |
| 40 |
PhaseV
PhaseV provides AI-driven solutions for efficient clinical development and opera…
|
Boston | 11 - 50 | $65.0M | Series A | 2025-05-13 |
| 41 |
XtalPi
XtalPi is a pharmaceutical technology company that is reinventing drug discovery…
|
Shenzhen | 501 - 1K | $2.3B | Post Ipo Debt | 2026-01-27 |
| 42 |
Antheia
Antheia uses synthetic biology to produce biosynthetic KSMs and APIs for essenti…
|
Menlo Park | 11 - 50 | $244.1M | Series C | 2025-06-03 |
| 43 |
Aspen Neuroscience
Aspen Neuroscience is a biotechnology company that specializes in personalized c…
|
San Diego | 101 - 250 | $387.0M | Series C | 2025-11-20 |
| 44 |
Pretzel Therapeutics
Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse m…
|
Waltham | 11 - 50 | $72.5M | Series Unknown | 2025-07-02 |
| 45 |
Multiply Labs
Multiply Labs deploys advanced robotics technology to manufacture personalized p…
|
San Francisco | 11 - 50 | $22.7M | Series A | 2021-04-14 |
| 46 |
LENZ Therapeutics
LENZ Therapeutics operates as an organization engaged in the late-stage clinical…
|
Del Mar | 51 - 100 | $217.4M | Post Ipo Equity | 2024-07-15 |
| 47 |
Disc Medicine
Disc Medicine is a biopharmaceutical company that develops therapies for hematol…
|
Watertown | 101 - 250 | $1.3B | Post Ipo Equity | 2025-10-21 |
| 48 |
Latent Labs
Latent Labs is a biology programmable to transform health and sustainability for…
|
London | 11 - 50 | $50.0M | Series A | 2025-02-13 |
| 49 |
LB Pharmaceuticals
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a …
|
New York | 11 - 50 | $233.2M | Post Ipo Equity | 2026-02-05 |
| 50 |
Enveda Biosciences
Enveda Biosciences is a biotechnology company that develops novel medications de…
|
Boulder | 101 - 250 | $529.9M | Series D | 2025-09-04 |